References
- Gonçalves de Lima O, D’Albuquerque IL, Machado MP, Silva E, Pinto GP. (1956). Primeiras observações sobre a ação antimicrobiana do lapachol. An Soc Biol Pe, 14:129–135.
- Gómez Castellanos JR, Prieto JM, Heinrich M. (2009). Red Lapacho (Tabebuia impetiginosa)–a global ethnopharmacological commodity? J Ethnopharmacol, 121:1–13.
- De Moura KCG, Emery FS, Neves-Pinto C, Pinto MCFR, Dantas AP., Salomão K, De Castro SL, Pinto AV. (2001). Trypanocidal activity of isolated naphthoquinones from Tabebuia and some heterocyclic derivatives: A review from an interdisciplinary study. Braz Chem Soc, 12:325–338.
- U.S. National Institute of Health. (2011). ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/results?term=ARQ+501. Accessed on 23 August 2011.
- Boveris A, Docampo R, Turrens JF, Stoppani AO. (1978). Effect of β-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi. Biochem J, 175:431–439.
- Docampo R, Lopes JN, Cruz FS, Souza W. (1977). Trypanosoma cruzi: Ultrastructural and metabolic alterations of epimastigotes by β-lapachone. Exp Parasitol, 42:142–149.
- Pinto AV, de Castro SL. (2009). The trypanocidal activity of naphthoquinones: A review. Molecules, 14:4570–4590.
- Cunha-Filho MS, Martínez-Pacheco R, Landín M. (2008). Dissolution rate enhancement of the novel antitumoral β-lapachone by solvent change precipitation of microparticles. Eur J Pharm Biopharm, 69:871–877.
- Malpani A. (2009). Promising novel approaches for oral delivery of poorly soluble drugs. Pharm Rev, 7. Available at http://www.pharmainfo.net/reviews/promising-novel-approaches-oral-delivery-poorly-soluble-drugsM. Accessed on October 20 2011.
- Alsaidan SM, Alsughayer AA, Eshra AG. (1998). Improved dissolution rate of indomethacin by adsorbents. Drug Dev Ind Pharm, 24:389–394.
- Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. (2007). Liquid–solid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm, 341:26–34.
- Johansen H, Moller N. (1978). Solvent deposition method for enhancement of dissolution rate: Importance of drug-to-excipient ratio. J Pharm Sci, 67:134–136.
- Dastmalchi S, Garjani A, Maleki N, Sheikhee G, Baghchevan V, Jafari-Azad P et al. (2005). Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent deposition technique. J Pharm Pharm Sci, 8:175–181.
- Cunha-Filho MS, Estévez-Braun A, Pérez-Sacau E, Echezarreta-López MM, Martínez-Pacheco R, Landín M. (2011). Light effect on the stability of β-lapachone in solution: Pathways and kinetics of degradation. J Pharm Pharmacol, 63:1156–1160.
- Fell JT, Newton JM. (1970). The prediction of the tensile strength of tablets. J Pharm Pharmacol, 22:247–248.
- U.S. Department of Health and Human Services. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070237.pdf. Accessed on 10 May 2011.
- Cunha-Filho MS, Dacunha-Marinho B, Torres-Labandeira JJ, Martínez-Pacheco R, Landín M. (2007). Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems. AAPS PharmSciTech, 8:E60.
- Khan KA, Rhodes CT. (1972). Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv, 47:594–607.
- Cunha-Filho MS, Landin M, Martinez-Pacheco R, Dacunha-Marinho B. (2006). β-lapachone. Acta Crystallogr C, 62:o473–o475.
- Li CJ, Li YZ, Pinto AV, Pardee AB. (1999). Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci USA, 96:13369–13374.
- Shapiro G, Supko JG, Ryan DP, Appelman L, Berkenblit A, Craig AR, et al. (2005). Eder Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors. Proceedings of 2005 ASCO Annual Meeting, Orlando, USA, 3042.